|Nasdaq:||GOOG BIIB NFLX IBB AMZN TSLA ILMN ALXN AMGN CHTR WYNN COST GMCR SIAL VRTX SLXP CELG WDC SBAC|
|Nyse:||ACT V LNKD PPG AGN MCK IVV GS LMT SPG FDX MMM IBM PXD NOC TWC APD HUM CMI GD|
|New Highs:||BIIB IBB SHW LNKD EQIX PPG LMT WHR SPG BWLD PRGO AVB MMM NOC APD HUM BXP FFIV ENR LLL|
Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization therapeutic products for the treatment for cardiovascular diseases in the United States. It develops products in the areas of lipid science and therapeutic benefits of polyunsaturated fatty acids. The company markets Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. It is also developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. The company was formerly known as Ethical Holdings plc. Amarin Corporation plc was founded in 1989 and is based in Dublin, Ireland.